Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM

Detalles Bibliográficos
Autores principales: Klopfenstein, Timothée, Gendrin, Vincent, Zayet, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212356/
https://www.ncbi.nlm.nih.gov/pubmed/35738319
http://dx.doi.org/10.1016/j.cmi.2022.06.013
_version_ 1784730566222938112
author Klopfenstein, Timothée
Gendrin, Vincent
Zayet, Souheil
author_facet Klopfenstein, Timothée
Gendrin, Vincent
Zayet, Souheil
author_sort Klopfenstein, Timothée
collection PubMed
description
format Online
Article
Text
id pubmed-9212356
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92123562022-06-22 Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM Klopfenstein, Timothée Gendrin, Vincent Zayet, Souheil Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-11 2022-06-20 /pmc/articles/PMC9212356/ /pubmed/35738319 http://dx.doi.org/10.1016/j.cmi.2022.06.013 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Klopfenstein, Timothée
Gendrin, Vincent
Zayet, Souheil
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title_full Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title_fullStr Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title_full_unstemmed Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title_short Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
title_sort re: early administration of tocilizumab in hospitalized covid-19 patients with elevated inflammatory markers; covidstorm
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212356/
https://www.ncbi.nlm.nih.gov/pubmed/35738319
http://dx.doi.org/10.1016/j.cmi.2022.06.013
work_keys_str_mv AT klopfensteintimothee reearlyadministrationoftocilizumabinhospitalizedcovid19patientswithelevatedinflammatorymarkerscovidstorm
AT gendrinvincent reearlyadministrationoftocilizumabinhospitalizedcovid19patientswithelevatedinflammatorymarkerscovidstorm
AT zayetsouheil reearlyadministrationoftocilizumabinhospitalizedcovid19patientswithelevatedinflammatorymarkerscovidstorm

Ejemplares similares